David Sallman, MD, Moffitt Cancer Center, Tampa, FL, shares some insights into the importance of targeting TP53 in acute myeloid leukemia (AML), and further highlights promising agents and combinations being explored, including eprenetapopt and combinations with magrolimab. This interview took place at the 18th International Symposium on Acute Leukemias (ISAL XVIII), held in Munich, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.